By: Stephanie Brown From: medicalxpress.com The U.S. Food and Drug Administration has granted de novo authorization to CLAIRITY BREAST, a first-in-class, image-based platform that can help predict a woman’s risk for breast cancer. CLAIRITY BREAST is designed as a prognostic tool that can predict the five-year risk of developing breast cancer by analyzing subtle imaging features on routine mammograms, making …
FDA Authorizes AI Platform for Breast Cancer Prediction
From: itnonline.com Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for Clairity Breast, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025 – propelling a new era …